Discounted Cash Flow
Vanda Pharmaceuticals Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $146.0m | $-18.0m | $-9.5m | -12.3% | $-0.41 |
| 2017 | $165.1m (13.1%) | $-15.6m (13.6%) | $-3.6m (61.7%) | -9.4% (23.5%) | $-0.35 (14.6%) |
| 2018 | $193.1m (17.0%) | $25.2m (261.9%) | $29.6m (912.1%) | 13.1% (238.4%) | $0.50 (242.9%) |
| 2019 | $227.2m (17.6%) | $115.6m (358.4%) | $44.9m (51.7%) | 50.9% (289.7%) | $2.17 (334.0%) |
| 2020 | $248.2m (9.2%) | $23.3m (-79.8%) | $50.0m (11.2%) | 9.4% (-81.5%) | $0.43 (-80.2%) |
| 2021 | $268.7m (8.3%) | $33.2m (42.1%) | $63.7m (27.4%) | 12.3% (31.2%) | $0.60 (39.5%) |
| 2022 | $254.4m (-5.3%) | $6.3m (-81.1%) | $31.3m (-50.8%) | 2.5% (-80.0%) | $0.11 (-81.7%) |
| 2023 | $192.6m (-24.3%) | $2.5m (-60.0%) | $12.4m (-60.3%) | 1.3% (-47.2%) | $0.04 (-63.6%) |
| 2024 | $198.8m (3.2%) | $-18.9m (-853.3%) | $-16.2m (-230.8%) | -9.5% (-830.0%) | $-0.33 (-925.0%) |
| 2025 | $216.1m (8.7%) | $-220.5m (-1066.5%) | $-110.4m (-579.8%) | -102.0% (-973.0%) | $-3.74 (-1033.3%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.